Optimizing treatment for patients with EGFR Ex20Ins-mutant non-small cell lung cancer (NSCLC) presents a significant challenge, often requiring a delicate balance between efficacy and safety. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.